Literature DB >> 25307854

Results of a two-year pilot study of clinical outcome measures in collagen VI- and laminin alpha2-related congenital muscular dystrophies.

Katherine G Meilleur1, Minal S Jain2, Linda S Hynan3, Ching-Yi Shieh4, Eunice Kim5, Melissa Waite2, Michelle McGuire6, Courtney Fiorini7, Allan M Glanzman8, Marion Main9, Kristy Rose10, Tina Duong11, Roxanna Bendixen12, Melody M Linton13, Irene C Arveson13, Carmel Nichols2, Kelly Yang14, Kenneth H Fischbeck14, Kathryn R Wagner7, Kathryn North10, Ami Mankodi14, Christopher Grunseich14, Elizabeth J Hartnett14, Michaele Smith2, Sandra Donkervoort14, Alice Schindler14, Angela Kokkinis14, Meganne Leach15, A Reghan Foley9, James Collins6, Francesco Muntoni9, Anne Rutkowski16, Carsten G Bönnemann17.   

Abstract

Potential therapies are currently under development for two congenital muscular dystrophy (CMD) subtypes: collagen VI-related muscular dystrophy (COL6-RD) and laminin alpha 2-related dystrophy (LAMA2-RD). However, appropriate clinical outcome measures to be used in clinical trials have not been validated in CMDs. We conducted a two-year pilot study to evaluate feasibility, reliability, and validity of various outcome measures, particularly the Motor Function Measure 32, in 33 subjects with COL6-RD and LAMA2-RD. In the first year, outcome measures tested included: Motor Function Measure 32 (MFM32), forced vital capacity (FVC) percent predicted sitting, myometry, goniometry, 10-meter walk, Egen Klassification 2, and PedsQL(TM) Generic and Neuromuscular Cores. In the second year, we added the North Star Ambulatory Assessment (NSAA), Hammersmith Functional Motor Scale (HFMS), timed functional tests, Measure of Activity Limitations (ACTIVLIM), Quality of Upper Extremity Skills Test (QUEST), and Patient-Reported Outcomes Measurement Information System (PROMIS) fatigue subscale. The MFM32 showed strong inter-rater (0.92) and internal consistency (0.96) reliabilities. Concurrent validity for the MFM32 was supported by large correlations (range 0.623-0.936) with the following: FVC, NSAA, HFMS, timed functional tests, ACTIVLIM, and QUEST. Significant correlations of the MFM32 were also found with select myometry measurements, mainly of the proximal extremities and domains of the PedsQL(TM) scales focusing on physical health and neuromuscular disease. Goniometry measurements were less reliable. The Motor Function Measure is reliable and valid in the two specific subtypes of CMD evaluated, COL6-RD and LAMA2-RD. The NSAA is useful as a complementary outcome measure in ambulatory individuals. Preliminary concurrent validity of several other clinical outcome measures was also demonstrated for these subtypes. Published by Elsevier B.V.

Entities:  

Keywords:  Clinical outcome measures; Collagen VI related muscular dystrophy; Laminin alpha 2 related dystrophy; Motor function scales; Neuromuscular disease

Mesh:

Substances:

Year:  2014        PMID: 25307854      PMCID: PMC5125840          DOI: 10.1016/j.nmd.2014.09.010

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  35 in total

1.  Development of a functional assessment scale for ambulatory boys with Duchenne muscular dystrophy.

Authors:  Elaine Scott; Michelle Eagle; Anna Mayhew; Jenny Freeman; Marion Main; Jennie Sheehan; Adnan Manzur; Francesco Muntoni
Journal:  Physiother Res Int       Date:  2011-09-23

2.  Natural history of Ullrich congenital muscular dystrophy.

Authors:  A Nadeau; M Kinali; M Main; C Jimenez-Mallebrera; A Aloysius; E Clement; B North; A Y Manzur; S A Robb; E Mercuri; F Muntoni
Journal:  Neurology       Date:  2009-07-07       Impact factor: 9.910

3.  Clinical and molecular cross-sectional study of a cohort of adult type III spinal muscular atrophy patients: clues from a biomarker study.

Authors:  Francesco D Tiziano; Rosa Lomastro; Lorena Di Pietro; Maria Barbara Pasanisi; Stefania Fiori; Carla Angelozzi; Emanuela Abiusi; Corrado Angelini; Gianni Sorarù; Alessandra Gaiani; Tiziana Mongini; Liliana Vercelli; Gessica Vasco; Giuseppe Vita; Gian Luca Vita; Sonia Messina; Luisa Politano; Luigia Passamano; Grazia Di Gregorio; Cristina Montomoli; Chiara Orsi; Angela Campanella; Renato Mantegazza; Lucia Morandi
Journal:  Eur J Hum Genet       Date:  2012-10-17       Impact factor: 4.246

4.  Development and psychometric properties of the PROMIS(®) pediatric fatigue item banks.

Authors:  Jin-Shei Lai; Brian D Stucky; David Thissen; James W Varni; Esi Morgan DeWitt; Debra E Irwin; Karin B Yeatts; Darren A DeWalt
Journal:  Qual Life Res       Date:  2013-02-02       Impact factor: 4.147

5.  The intraclass correlation coefficient as a measure of reliability.

Authors:  J J Bartko
Journal:  Psychol Rep       Date:  1966-08

6.  Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy.

Authors:  Jill E Mayhew; Julaine M Florence; Thomas P Mayhew; Erik K Henricson; Robert T Leshner; Robert J McCarter; Diana M Escolar
Journal:  Muscle Nerve       Date:  2007-01       Impact factor: 3.217

7.  Perception of quality of life by patients, partners and treating physicians.

Authors:  K A Wilson; A J Dowling; M Abdolell; I F Tannock
Journal:  Qual Life Res       Date:  2000       Impact factor: 4.147

8.  Reliability of 4 outcome measures in pediatric spinal muscular atrophy.

Authors:  Susan T Iannaccone; Linda S Hynan
Journal:  Arch Neurol       Date:  2003-08

9.  Participation and quality of life in children with Duchenne muscular dystrophy using the International Classification of Functioning, Disability, and Health.

Authors:  Roxanna M Bendixen; Claudia Senesac; Donovan J Lott; Krista Vandenborne
Journal:  Health Qual Life Outcomes       Date:  2012-05-22       Impact factor: 3.186

10.  Hammersmith Functional Motor Scale and Motor Function Measure-20 in non ambulant SMA patients.

Authors:  E Mazzone; R De Sanctis; L Fanelli; F Bianco; M Main; M van den Hauwe; M Ash; R de Vries; J Fagoaga Mata; K Schaefer; A D'Amico; G Colia; C Palermo; M Scoto; A Mayhew; M Eagle; L Servais; M Vigo; A Febrer; R Korinthenberg; M Jeukens; M de Viesser; A Totoescu; T Voit; K Bushby; F Muntoni; N Goemans; E Bertini; M Pane; E Mercuri
Journal:  Neuromuscul Disord       Date:  2014-01-16       Impact factor: 4.296

View more
  13 in total

1.  Upper extremity outcome measures for collagen VI-related myopathy and LAMA2-related muscular dystrophy.

Authors:  Roxanna M Bendixen; Jocelyn Butrum; Mina S Jain; Rebecca Parks; Bonnie Hodsdon; Carmel Nichols; Michelle Hsia; Leslie Nelson; Katherine C Keller; Michelle McGuire; Jeffrey S Elliott; Melody M Linton; Irene C Arveson; Fatou Tounkara; Ruhi Vasavada; Elizabeth Harnett; Monal Punjabi; Sandra Donkervoort; Jahannaz Dastgir; Meganne E Leach; Anne Rutkowski; Melissa Waite; James Collins; Carsten G Bönnemann; Katherine G Meilleur
Journal:  Neuromuscul Disord       Date:  2016-12-05       Impact factor: 4.296

2.  Electrical impedance myography in individuals with collagen 6 and laminin α-2 congenital muscular dystrophy: a cross-sectional and 2-year analysis.

Authors:  Carmel Nichols; Minal S Jain; Katherine G Meilleur; Tianxia Wu; James Collins; Melissa R Waite; Jahannaz Dastgir; Anam Salman; Sandra Donkervoort; Tina Duong; Katherine Keller; Meganne E Leach; Donovan J Lott; Michelle N McGuire; Leslie Nelson; Anne Rutkowski; Carole Vuillerot; Carsten G Bönnemann; Tanya J Lehky
Journal:  Muscle Nerve       Date:  2017-04-25       Impact factor: 3.217

3.  Longitudinal changes in clinical outcome measures in COL6-related dystrophies and LAMA2-related dystrophies.

Authors:  Minal S Jain; Katherine Meilleur; Eunhee Kim; Gina Norato; Melissa Waite; Leslie Nelson; Michelle McGuire; Tina Duong; Katherine Keller; Donovan J Lott; Allan Glanzman; Kristy Rose; Marion Main; Courtney Fiorini; Irene Chrismer; Melody Linton; Monal Punjabi; Jeffrey Elliott; Fatoumata Tounkara; Ruhi Vasavada; Ranjani Logaraj; Jocelyn Winkert; Sandra Donkervoort; Meganne Leach; Jahannaz Dastgir; Linda Hynan; Carmel Nichols; Elizabeth Hartnett; Gilberto M Averion; James C Collins; Eunice S Kim; Angela Kokkinis; Alice Schindler; Kristen Zukosky; Robert Fee; Veronica Hinton; Payam Mohassel; Diana Bharucha-Goebel; Carole Vuillerot; Peter McGraw; Mark Barton; Joseph Fontana; Anne Rutkowski; A Reghan Foley; Carsten G Bönnemann
Journal:  Neurology       Date:  2019-10-25       Impact factor: 9.910

4.  Association of Initial Maximal Motor Ability With Long-term Functional Outcome in Patients With COL6-Related Dystrophies.

Authors:  Daniel Natera-de Benito; A Reghan Foley; Cristina Domínguez-González; Carlos Ortez; Minal Jain; Aron Mebrahtu; Sandra Donkervoort; Ying Hu; Margaret Fink; Pomi Yun; Tracy Ogata; Julita Medina; Meritxell Vigo; Katherine G Meilleur; Meganne E Leach; Jahannaz Dastgir; Jordi Díaz-Manera; Laura Carrera-García; Jessica Expósito-Escudero; Macarena Alarcon; Daniel Cuadras; Elena Montiel-Morillo; José C Milisenda; Raul Dominguez-Rubio; Montse Olivé; Jaume Colomer; Cristina Jou; Cecilia Jimenez-Mallebrera; Carsten G Bönnemann; Andres Nascimento
Journal:  Neurology       Date:  2021-01-13       Impact factor: 9.910

5.  Reliability of home-based, motor function measure in hereditary neuromuscular diseases.

Authors:  Xiomara Ruiz-Cortes; Fernando Ortiz-Corredor; Camilo Mendoza-Pulido
Journal:  J Int Med Res       Date:  2017-01-12       Impact factor: 1.671

6.  Differences in Adipose Tissue and Lean Mass Distribution in Patients with Collagen VI Related Myopathies Are Associated with Disease Severity and Physical Ability.

Authors:  M A Rodríguez; Luís M Del Rio Barquero; Carlos I Ortez; Cristina Jou; Meritxell Vigo; Julita Medina; Anna Febrer; Marta Ramon-Krauel; Jorge Diaz-Manera; Montse Olive; Laura González-Mera; Andres Nascimento; Cecilia Jimenez-Mallebrera
Journal:  Front Aging Neurosci       Date:  2017-08-08       Impact factor: 5.750

Review 7.  Walking and weakness in children: a narrative review of gait and functional ambulation in paediatric neuromuscular disease.

Authors:  Rachel A Kennedy; Kate Carroll; Jennifer L McGinley; Kade L Paterson
Journal:  J Foot Ankle Res       Date:  2020-03-02       Impact factor: 2.303

8.  Lower Extremity Muscle Involvement in the Intermediate and Bethlem Myopathy Forms of COL6-Related Dystrophy and Duchenne Muscular Dystrophy: A Cross-Sectional Study.

Authors:  Abhinandan Batra; Donovan J Lott; Rebecca Willcocks; Sean C Forbes; William Triplett; Jahannaz Dastgir; Pomi Yun; A Reghan Foley; Carsten G Bönnemann; Krista Vandenborne; Glenn A Walter
Journal:  J Neuromuscul Dis       Date:  2020

9.  Effect of Periodic Granulocyte Colony-Stimulating Factor Administration on Endothelial Progenitor Cells and Different Monocyte Subsets in Pediatric Patients with Muscular Dystrophies.

Authors:  Andrzej Eljaszewicz; Dorota Sienkiewicz; Kamil Grubczak; Bożena Okurowska-Zawada; Grażyna Paszko-Patej; Paula Miklasz; Paulina Singh; Urszula Radzikowska; Wojciech Kulak; Marcin Moniuszko
Journal:  Stem Cells Int       Date:  2015-12-06       Impact factor: 5.443

Review 10.  Treating pediatric neuromuscular disorders: The future is now.

Authors:  James J Dowling; Hernan D Gonorazky; Ronald D Cohn; Craig Campbell
Journal:  Am J Med Genet A       Date:  2017-09-10       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.